A plan to develop, through joint research with Q Therapeutics and others, iPS cell-derived neural glial cells as regenerative medicine products for central nervous system diseases such as ALS and transverse myelitis, with the aim of starting clinical trials. The theme covers the ongoing process from evaluating efficacy and cell engraftment in preclinical studies through preparation for clinical trials.